Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$37.5B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical industry, focusing on generic and specialty medications. With a market cap of $37 billion, Teva plays a crucial role in healthcare by providing affordable medicines and addressing various medical needs.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and performance, which investors closely watch during earnings reports.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1 2026, Teva reported an EPS of $0.53, surpassing expectations by 8.83%. The stock reacted positively, rising 11.89% the following day.

Management Promises & Guidance

Focus on expanding generic drug offerings.
Commitment to improving operational efficiencies.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Teva's upcoming earnings, given its strong performance in previous quarters.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential.

Bear Case

Concerns about market competition and pricing pressures could lead to disappointing results, impacting investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's strong track record of beating EPS estimates, this number will be crucial for investor confidence.

How is Teva addressing competition in the generic drug market?

Understanding Teva's strategy to maintain its market position will be key to assessing its future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its extensive portfolio of generic drugs, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Teva has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing a smaller move than historical averages, suggesting potential upside.

Recent trends in the pharmaceutical sector show increasing demand for generics, which could benefit Teva.

Key Risk

If Teva's revenue growth exceeds expectations, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Teva's ability to sustain growth in a competitive landscape, making EPS a critical measure this quarter.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, raising concerns about competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a move of about 5.66%, indicating some uncertainty ahead of the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by an average of 3.79%, confirming strong operational health.

In-Line / Cautious

A cautious inline report may lead to muted reactions as investors await further clarity on future guidance.

Miss

If Teva misses expectations, history suggests a potential decline of around 3.79%, raising concerns about its competitive position.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the competitive landscape in the generic drug market.
2Any new product launches or pipeline developments.
3Management's outlook on revenue growth for the upcoming quarters.
4Details on cost management and operational efficiencies.
5Insights into market demand trends for Teva's products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and performance, which investors closely watch during earnings reports.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and market share, which is vital for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TEVA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q1 2026, Teva reported an EPS of $0.53, surpassing expectations by 8.83%. The stock reacted positively, rising 11.89% the following day.

Management Promises & Guidance

Focus on expanding generic drug offerings.
Commitment to improving operational efficiencies.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Teva's upcoming earnings, given its strong performance in previous quarters.

Bull Case

If Teva continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential.

Bear Case

Concerns about market competition and pricing pressures could lead to disappointing results, impacting investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Teva's strong track record of beating EPS estimates, this number will be crucial for investor confidence.

How is Teva addressing competition in the generic drug market?

Understanding Teva's strategy to maintain its market position will be key to assessing its future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Teva's ability to leverage its extensive portfolio of generic drugs, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Teva has consistently beaten EPS estimates in the past, indicating strong operational execution.

The options market is pricing a smaller move than historical averages, suggesting potential upside.

Recent trends in the pharmaceutical sector show increasing demand for generics, which could benefit Teva.

Key Risk

If Teva's revenue growth exceeds expectations, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Teva's ability to sustain growth in a competitive landscape, making EPS a critical measure this quarter.

Bull Confirmed If

An EPS of $0.55 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.50 would confirm the bear case, raising concerns about competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±5.66%

Historical Avg

±9.0%

Pricing cheap

The options market is pricing in a move of about 5.66%, indicating some uncertainty ahead of the earnings report.

Options are pricing ±5.7% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

39.9%

Calls (108K)P/C Ratio: 0.30Puts (114K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by an average of 3.79%, confirming strong operational health.

In-Line / Cautious

A cautious inline report may lead to muted reactions as investors await further clarity on future guidance.

Miss

If Teva misses expectations, history suggests a potential decline of around 3.79%, raising concerns about its competitive position.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the competitive landscape in the generic drug market.
2Any new product launches or pipeline developments.
3Management's outlook on revenue growth for the upcoming quarters.
4Details on cost management and operational efficiencies.
5Insights into market demand trends for Teva's products.